SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its...
Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy
SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its...
1 April 2025
Gilde Healthcare announces successful sale of health-it software company Performation to Enovation, part of Legrand
Exit confirms Gilde Healthcare's investment strategy of building market-leading healthcare companies that deliver better care at lower cost Under ownership of Gilde Healthcare’s private equity fund, Performation has evolved into...
13 February 2025
Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy
SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its...
1 April 2025
Filter & search
Fund strategy:
Loading...
These were all articles
e664176892